Novartis raises blockbuster drug forecasts to $18 billion as it seeks to prove growth can last
The drugmaker cited strong demand for its blockbuster drugs as it upgraded peak sales forecasts for multiple sclerosis, leukemia, and cholesterol medicines.
Full story
Read the full story at CNBC ↗
Continue reading this story on CNBC, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.